Research programme: cancer therapeutics - Cotinga Pharmaceuticals

Drug Profile

Research programme: cancer therapeutics - Cotinga Pharmaceuticals

Alternative Names: COTI-04; COTI-219; COTI-4A; COTI-58

Latest Information Update: 10 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Critical Outcome Technologies
  • Developer Cotinga Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; Cyclin-dependent kinase modulators; Iron chelating agents; KRAS protein inhibitors; Methylenetetrahydrofolate reductase modulators; P53 gene modulators; Proto oncogene protein c-akt inhibitors; Thymidylate synthase expression modulators; Tubulin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Small cell lung cancer
  • Research Colorectal cancer

Most Recent Events

  • 08 Jan 2018 Critical Outcome Technologies is now called Cotinga Pharmaceuticals
  • 05 Jan 2018 Development is ongoing for COTI 219, COTI 04 and COTI 58 (Critical Outcome Technologies Pipeline; 9230143)
  • 28 Dec 2017 No recent reports of development identified for research development in Colorectal-cancer in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top